NXST:NASDAQNexstar Media Group, Inc. Analysis
Data as of 2026-04-21 - not real-time
$208.65
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Nexstar (NXST) is trading at $208.65, comfortably above its 20‑day SMA ($195.34) and 200‑day SMA ($204.09) but below the 50‑day SMA ($221.19), indicating a short‑term bullish tilt within a neutral longer‑term trend. The RSI sits at 54 and the MACD histogram is positive, reinforcing modest upside momentum, while volume has been declining and 30‑day volatility is high at 54%, suggesting price swings may be pronounced. Valuation metrics are mixed: a trailing P/E of 69.5 far exceeds the industry average of 19.2, yet the forward P/E of 11.6 and a DCF‑derived fair value of $213.5 imply the stock may be nearing its intrinsic worth, with a calculated upside of roughly 25%. Dividend sustainability is a concern as the 3.62% yield is backed by a payout ratio of 248%, well above sustainable levels.
The recent closure of the TEGNA acquisition and the issuance of $5.1 B in senior notes dramatically increase leverage, pushing the debt‑to‑equity ratio above 300 and raising balance‑sheet risk. Insider sales by senior executives further temper confidence. However, operating margins remain solid (20.5% operating, 2.2% net) and free cash flow is positive, providing a cushion for integration. With the market in “Extreme Greed” mode (Fear & Greed Index 86) and analysts averaging a “strong buy” rating, the stock sits at a crossroads between short‑term volatility and longer‑term strategic upside.
The recent closure of the TEGNA acquisition and the issuance of $5.1 B in senior notes dramatically increase leverage, pushing the debt‑to‑equity ratio above 300 and raising balance‑sheet risk. Insider sales by senior executives further temper confidence. However, operating margins remain solid (20.5% operating, 2.2% net) and free cash flow is positive, providing a cushion for integration. With the market in “Extreme Greed” mode (Fear & Greed Index 86) and analysts averaging a “strong buy” rating, the stock sits at a crossroads between short‑term volatility and longer‑term strategic upside.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Positive MACD histogram and price above short‑term SMA
- High short‑term volatility and decreasing volume
- Pending Q1 earnings and integration risk from TEGNA deal
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward P/E compression to 11.6 indicating earnings growth
- DCF upside of ~25% and fair value near current price
- Strategic scale benefits from TEGNA acquisition
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Elevated leverage and unsustainable dividend payout
- Stable operating margins and positive free cash flow
- Potential regulatory and integration headwinds
Key Metrics & Analysis
Financial Health
Revenue Growth-13.30%
Profit Margin2.20%
P/E Ratio69.5
ROE3.83%
ROA5.01%
Debt/Equity320.85
P/B Ratio3.1
Op. Cash Flow$891.0M
Free Cash Flow$941.9M
Industry P/E19.2
Technical Analysis
TrendNeutral
RSI54.0
Support$173.02
Resistance$228.67
MA 20$195.34
MA 50$221.19
MA 200$204.09
MACDBullish
VolumeDecreasing
Fear & Greed Index86.14
Valuation
Fair Value$213.50
Target Price$261.25
Upside/Downside25.21%
GradeFair
TypeBlend
Dividend Yield3.62%
Risk Assessment
Beta0.68
Volatility54.04%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.